These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26877068)

  • 41. Acetaminophen and other risk factors for excessive warfarin anticoagulation.
    Hylek EM; Heiman H; Skates SJ; Sheehan MA; Singer DE
    JAMA; 1998 Mar; 279(9):657-62. PubMed ID: 9496982
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Factors influencing warfarin dose requirements in African-Americans.
    Momary KM; Shapiro NL; Viana MA; Nutescu EA; Helgason CM; Cavallari LH
    Pharmacogenomics; 2007 Nov; 8(11):1535-44. PubMed ID: 18034618
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
    An SH; Lee KE; Chang BC; Gwak HS
    J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort.
    Perini JA; Struchiner CJ; Silva-Assunção E; Suarez-Kurtz G
    Clin Pharmacol Ther; 2010 Apr; 87(4):417-20. PubMed ID: 20182420
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population.
    Kudzi W; Ahorhorlu SY; Dzudzor B; Olayemi E; Nartey ET; Asmah RH
    BMC Res Notes; 2016 Dec; 9(1):507. PubMed ID: 27938396
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in Chinese valve replacement patients.
    Li JH; Ma GG; Zhu SQ; Yan H; Wu YB; Xu JJ
    J Cardiothorac Surg; 2012 Sep; 7():97. PubMed ID: 23013706
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population.
    Giri AK; Khan NM; Grover S; Kaur I; Basu A; Tandon N; Scaria V; ; ; Kukreti R; Brahmachari SK; Bharadwaj D
    Pharmacogenomics; 2014 Jul; 15(10):1337-54. PubMed ID: 25155935
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association between apolipoprotein E genotype and warfarin response during initial anticoagulation.
    He S; Zhang H; Cao Y; Nian F; Chen H; Chen W; Auchoybur ML; Yin L; Tao Z; Tang S; Chen X
    Biomed Pharmacother; 2018 May; 101():251-256. PubMed ID: 29494962
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of the CYP4F2 polymorphism on the risk of hemorrhagic complications in coumarin-treated patients.
    Chen P; Sun YQ; Yang GP; Li R; Pan J; Zhou YS
    Saudi Med J; 2016 Apr; 37(4):361-8. PubMed ID: 27052278
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study.
    Limdi NA; Nolin TD; Booth SL; Centi A; Marques MB; Crowley MR; Allon M; Beasley TM
    Am J Kidney Dis; 2015 May; 65(5):701-9. PubMed ID: 25468385
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy.
    Limdi NA; Beasley TM; Allison DB; Rivers CA; Acton RT
    Blood Cells Mol Dis; 2006; 37(2):100-6. PubMed ID: 16889993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent.
    De T; Alarcon C; Hernandez W; Liko I; Cavallari LH; Duarte JD; Perera MA
    JAMA; 2018 Oct; 320(16):1670-1677. PubMed ID: 30357299
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.
    Limdi NA; McGwin G; Goldstein JA; Beasley TM; Arnett DK; Adler BK; Baird MF; Acton RT
    Clin Pharmacol Ther; 2008 Feb; 83(2):312-21. PubMed ID: 17653141
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Warfarin-antibiotic interactions in older adults of an outpatient anticoagulation clinic.
    Ghaswalla PK; Harpe SE; Tassone D; Slattum PW
    Am J Geriatr Pharmacother; 2012 Dec; 10(6):352-60. PubMed ID: 23089199
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.
    Gage BF; Bass AR; Lin H; Woller SC; Stevens SM; Al-Hammadi N; Li J; Rodríguez T; Miller JP; McMillin GA; Pendleton RC; Jaffer AK; King CR; Whipple BD; Porche-Sorbet R; Napoli L; Merritt K; Thompson AM; Hyun G; Anderson JL; Hollomon W; Barrack RL; Nunley RM; Moskowitz G; Dávila-Román V; Eby CS
    JAMA; 2017 Sep; 318(12):1115-1124. PubMed ID: 28973620
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves.
    Lee KE; Chang BC; Kim HO; Yoon IK; Lee NR; Park HY; Gwak HS
    Ther Drug Monit; 2012 Jun; 34(3):275-82. PubMed ID: 22549502
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting.
    Hart R; Veenstra DL; Boudreau DM; Roth JA
    Am J Med; 2017 Feb; 130(2):222-228. PubMed ID: 27593608
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy.
    Zhang JE; Jorgensen AL; Alfirevic A; Williamson PR; Toh CH; Park BK; Pirmohamed M
    Pharmacogenet Genomics; 2009 Oct; 19(10):781-9. PubMed ID: 19741565
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Brandão LR; Ito S
    Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.